1/7/2019 7:34:49 AM
Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) FY19 Estimate To -2.79 From -2.48
1/7/2019 7:34:27 AM
Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) Q4 19 Estimate To -0.70 From -0.63
1/7/2019 7:34:21 AM
Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q3 19 Estimate To -0.70 From -0.63
1/7/2019 7:34:06 AM
Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q2 19 Estimate To -0.69 From -0.61
1/7/2019 7:33:58 AM
Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q1 19 Estimate To -0.69 From -0.61
1/7/2019 7:29:32 AM
Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $15 Price Target
1/4/2019 7:05:03 AM
Mersana Therapeutics Announces Strategic Priorities And Goals For 2019 And Beyond
11/13/2018 7:11:33 AM
Mersana Therapeutics Q3 Loss Per Share $0.75 Vs Loss $0.35 Last Year
11/12/2018 9:16:29 AM
Mersana Presents Pre-clinical Data At AACR-NCI-EORTC On Two Additional, Proprietary Antibody Drug Conjugate Platform
9/25/2018 8:06:19 AM
Mersana Therapeutics Presents New Preclinical Data On XMT-1536 At IASLC
9/18/2018 6:40:24 AM
Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $15 Down From $16 Price Target
9/17/2018 7:03:50 AM
Mersana Therapeutics: FDA Lifts Partial Clinical Hold For XMT-1522
8/14/2018 4:27:13 PM
Mersana Therapeutics Q2 Loss/share $0.54 Vs. Loss $6.33 Year Ago
7/19/2018 8:11:25 AM
Mersana Therapeutics Says FDA Placed Phase 1 Study Of XMT-1522 On Partial Clinical Hold
5/15/2018 7:39:26 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) FY18 Rev. Estimate To 13.9 M From 11.0 M
5/15/2018 7:39:14 AM
Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q4 18 Rev. Estimate To 3.6 M From 2.7 M